Molecular Devices and HeartBeat.bio launch 3D Ready™ Cardioid Supplement Kits
10 August 2026
Built on HeartBeat.bio's cardiac organoid technology and Molecular Devices’ expertise in automation and analysis, the 3D Ready™ Cardioid Supplement Kit is the first commercial offering from the long-term collaboration of the two companies.
This joint project reflects the sector’s move toward standardized, reproducible, and scalable in vitro solutions designed to improve predictivity and reduce barriers to adoption.
The portfolio includes two options. The single-lineage cardioid kit generates cardiomyocyte-only cardiac organoids for cardiac biology and toxicity studies, while the tri-lineage cardioid kit produces cardiac organoids containing cardiomyocytes, endothelial cells, and fibroblasts, enabling investigation of fibrosis, chronic toxicity, and other mechanisms of cardiac toxicity.
"Researchers are under increasing pressure to make faster, more informed decisions while reducing risk throughout the drug development process." said Mary Duseau, President of Molecular Devices. "Together with HeartBeat.bio, we're helping make advanced cardiac organoid models more accessible and reproducible, enabling researchers to generate insights earlier and with greater confidence. By combining leading biology with scalable automation and analysis, we're helping accelerate the journey from scientific discovery to safer medicines."
"Cardiac safety remains one of the greatest challenges in drug development, and more predictive human model systems are essential to improve decision-making before compounds reach the clinic," said Michael Krebs, CEO of HeartBeat.bio. "By combining our Cardioid technology with Molecular Devices' expertise in the automation and integration of scalable workflows, we are making advanced human cardiac models more broadly accessible to the research community. Together, we aim to enable more predictive cardiac safety assessment and help accelerate the development of safer medicines."
This newly developed offering was successfully validated by the CRO Axxam at both the phenotypic and functional levels, demonstrating the platform's robustness, reproducibility, and potential for translational drug discovery applications.
For weekly news, trends and insights on human‑based in vitro approaches, explore your access options.
